Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GOVX

Geovax Labs Inc

Jun 21 • 04:00PM ET

2.33

Dollar change +0.44
Percentage change 23.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-14.45	Insider Own	1.45%	Shs Outstand	2.53M	Perf Week	66.43%
Market Cap	5.89M	Forward P/E	-	EPS next Y	-1.76	Insider Trans	92.96%	Shs Float	2.49M	Perf Month	44.72%
Income	-27.78M	PEG	-	EPS next Q	-4.43	Inst Own	9.52%	Short Float	1.80%	Perf Quarter	20.73%
Sales	0.00M	P/S	-	EPS this Y	38.98%	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-52.51%
Book/sh	0.02	P/B	99.11	EPS next Y	79.82%	ROA	-180.60%	Short Interest	0.04M	Perf Year	-74.72%
Cash/sh	0.30	P/C	7.66	EPS next 5Y	-	ROE	-242.41%	52W Range	1.09 - 10.24	Perf YTD	-56.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	92.12%	ROI	-51181.90%	52W High	-77.25%	Beta	2.99
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	-20.34%	Gross Margin	-	52W Low	113.74%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	0.87	EPS Y/Y TTM	-37.03%	Oper. Margin	0.00%	RSI (14)	67.78	Volatility	39.40% 19.54%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	-7.47%	Payout	-	Rel Volume	12.32	Prev Close	1.89
Sales Surprise	-	EPS Surprise	55.58%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	797.15K	Price	2.33
SMA20	40.90%	SMA50	44.14%	SMA200	-47.07%	Trades		Volume	9,822,031	Change	23.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-20	Initiated	Maxim Group	Buy	$8

Jun-20-24 10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
Jun-18-24 07:00AM	GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 (NewMediaWire) +71.17%
Jun-07-24 07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -6.40%
May-29-24 09:00AM	GeoVax to Present at BIO International Convention 2024 (NewMediaWire) +7.98%
May-17-24 08:00AM	GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market (NewMediaWire)
08:19AM	Loading…
May-15-24 08:19AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:53AM	GOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024 (InvestorPlace)
May-14-24 04:00PM	GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update (NewMediaWire)
May-07-24 09:00AM	GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 (NewMediaWire)
Apr-04-24 12:30PM	GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine (GlobeNewswire)
Mar-28-24 09:00AM	GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress (GlobeNewswire) +8.11%
Mar-12-24 09:00AM	GeoVax to Present at the 36th Annual Roth Conference (GlobeNewswire)
Mar-06-24 09:00AM	GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System (GlobeNewswire)
Mar-02-24 08:45AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 04:00PM	GeoVax Reports 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
09:00AM	Loading…
Feb-22-24 09:00AM	GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 (GlobeNewswire)
Feb-19-24 09:00AM	GeoVax to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-13-24 09:00AM	GeoVax Announces Multiple Patent Issuances and Allowances (GlobeNewswire)
Feb-06-24 09:00AM	GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster (GlobeNewswire)
Jan-29-24 09:00AM	GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement (GlobeNewswire) -8.25%
Jan-08-24 09:00AM	GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology (GlobeNewswire)
Jan-04-24 09:00AM	GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients (GlobeNewswire)
Jan-03-24 09:00AM	GeoVax Announces Issuance of Malaria Vaccine Patent (GlobeNewswire)
Dec-27-23 09:00AM	GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 (GlobeNewswire)
Dec-19-23 09:00AM	GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox (GlobeNewswire)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 04:30PM	GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress (GlobeNewswire)
Nov-29-23 09:00AM	GeoVax to Participate in Upcoming December Investor Events (GlobeNewswire)
Nov-28-23 09:00AM	GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress (GlobeNewswire)
09:00AM	Loading…
Nov-14-23 09:00AM	Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 (GlobeNewswire)
Nov-10-23 10:24AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:00PM	GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-31-23 09:00AM	GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-30-23 09:00AM	GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine (GlobeNewswire)
Oct-25-23 09:00AM	GeoVax to Participate in Upcoming November Investor and Industry Events (GlobeNewswire)
Oct-24-23 09:00AM	GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities (GlobeNewswire)
Oct-09-23 09:00AM	GeoVax Receives Notice of Allowance for Marburg Vaccine Patent (GlobeNewswire)
Oct-05-23 09:00AM	GeoVax Receives Notice of Allowance for HIV Vaccine Patent (GlobeNewswire) +5.54%
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.81%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 09:00AM	GeoVax to Participate in Upcoming October Investor and Industry Events (GlobeNewswire)
Sep-26-23 09:00AM	GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-20-23 09:00AM	GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference (GlobeNewswire)
Sep-19-23 09:00AM	GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients (GlobeNewswire)
Sep-12-23 09:00AM	GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-11-23 09:00AM	GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster (GlobeNewswire)
Aug-31-23 09:00AM	GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -5.02%
Aug-29-23 09:00AM	GeoVax to Present at the Emerging Growth Conference on September 6, 2023 (GlobeNewswire)
Aug-28-23 09:00AM	GeoVax Receives Notice of Allowance for Malaria Vaccine Patent (GlobeNewswire)
Aug-11-23 12:47PM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:00AM	GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Aug-09-23 04:00PM	GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 09:00AM	GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 (GlobeNewswire) +11.62%
Jul-24-23 09:00AM	GeoVax Announces Issuance of Ebola Vaccine Patent (GlobeNewswire)
Jul-20-23 09:00AM	GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Jul-10-23 09:00AM	GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference (GlobeNewswire)
Jun-28-23 09:00AM	GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference (GlobeNewswire)
Jun-27-23 10:15AM	GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights (GlobeNewswire)
May-31-23 09:00AM	GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates (GlobeNewswire)
May-25-23 09:00AM	GeoVax to Participate in Upcoming Industry Meetings (GlobeNewswire) -10.67%
May-24-23 04:32PM	GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results (Benzinga) +14.17%
08:00AM	GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients (GlobeNewswire)
May-15-23 09:00AM	GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings (GlobeNewswire)
May-09-23 09:00AM	GeoVax Labs to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-04-23 04:00PM	GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +8.15%
Apr-26-23 09:00AM	GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host (GlobeNewswire)
Apr-25-23 09:00AM	GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 (GlobeNewswire)
Apr-17-23 09:00AM	GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses (GlobeNewswire)
Apr-06-23 10:00AM	GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate (GlobeNewswire)
Apr-05-23 01:30PM	GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress (GlobeNewswire)
Mar-30-23 11:00AM	GeoVax to Participate at the World Vaccine Congress with Multiple Presentations (GlobeNewswire)
Mar-27-23 07:08AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2022 Earnings Call Transcript (Insider Monkey) -6.22%
Mar-23-23 04:00PM	GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update (GlobeNewswire) -6.20%
Mar-15-23 09:00AM	GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress (GlobeNewswire)
Mar-09-23 09:00AM	GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update (GlobeNewswire)
Mar-06-23 09:00AM	GeoVax to Participate at the 35th Annual Roth Conference (GlobeNewswire) -6.64%
Feb-27-23 09:00AM	GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections (GlobeNewswire) -8.27%
Feb-15-23 09:00AM	GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial (GlobeNewswire)
Feb-08-23 09:00AM	GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines (GlobeNewswire)
Feb-07-23 09:00AM	GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers (GlobeNewswire)
Jan-26-23 09:00AM	GeoVax to Present at the 2023 BIO CEO & Investor Conference (GlobeNewswire) -32.33%
Jan-25-23 11:00AM	GeoVax Receives Notice of Allowance for Zika Vaccine Patent (GlobeNewswire) +58.89%
Jan-04-23 09:00AM	GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 (GlobeNewswire)
Dec-20-22 09:00AM	Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax (GlobeNewswire)
Dec-07-22 04:00PM	GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors (GlobeNewswire)
Nov-28-22 10:15AM	GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 (GlobeNewswire)
Nov-11-22 05:46AM	GeoVax Labs Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021) (Simply Wall St.) +7.50%
Nov-09-22 04:00PM	GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -8.77%
Oct-31-22 10:33AM	Will GeoVax Labs (NASDAQ:GOVX) Spend Its Cash Wisely? (Simply Wall St.)
Oct-26-22 09:00AM	GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 (GlobeNewswire) +27.02%
Oct-11-22 09:00AM	GeoVax to Present at Vaccines Summit-2022 (GlobeNewswire)
Oct-06-22 09:00AM	GeoVax to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-07-22 09:00AM	GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 09:00AM	GeoVax Announces Addition to Its Board of Directors (GlobeNewswire)
Aug-18-22 10:27AM	GeoVax Labs Stock Is a Monkeypox Meme Play for Bold Traders (InvestorPlace) -12.83%
Aug-17-22 09:29AM	7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher (InvestorPlace)

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DODD DAVID A	President, CEO	Feb 22 '24	Buy	2.27	8,209	18,663	18,661	Feb 22 04:41 PM
DODD DAVID A	President, CEO	Feb 21 '24	Buy	2.15	520	1,118	10,452	Feb 22 04:41 PM
Reynolds Mark	CFO	Feb 07 '24	Buy	2.77	2,000	5,540	7,213	Feb 07 04:43 PM
McKee Kelly T. Jr.	Chief Medical Officer	Dec 22 '23	Buy	0.36	6,944	2,500	35,782	Dec 26 03:51 PM
McKee Kelly T. Jr.	Chief Medical Officer	Sep 25 '23	Buy	0.52	9,653	5,020	28,838	Sep 27 04:33 PM
DODD DAVID A	President, CEO	Aug 25 '23	Buy	0.57	35,087	20,000	148,957	Aug 28 04:05 PM
Reynolds Mark	CFO	Aug 18 '23	Buy	0.52	10,000	5,179	78,184	Aug 21 08:39 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOVX

Geovax Labs Inc

Upgrade your FINVIZ experience